These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

502 related articles for article (PubMed ID: 8197926)

  • 1. Design and analysis of prostate cancer trials.
    Sylvester R
    Acta Urol Belg; 1994 Apr; 62(1):23-9. PubMed ID: 8197926
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Statistical considerations for the design and analysis of Phase III clinical trials in prostate cancer.
    Halabi S
    Urol Oncol; 2008; 26(3):300-7. PubMed ID: 18452825
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Performance of adaptive sample size adjustment with respect to stopping criteria and time of interim analysis.
    Jahn-Eimermacher A; Hommel G
    Stat Med; 2007 Mar; 26(7):1450-61. PubMed ID: 16900553
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic factors for randomization and stratification and endpoints for the evaluation of trials.
    Sylvester RJ; Suciu S; Yamanaka H
    Prog Clin Biol Res; 1988; 269():275-87. PubMed ID: 3293065
    [No Abstract]   [Full Text] [Related]  

  • 5. Randomized phase II designs in cancer clinical trials: current status and future directions.
    Lee JJ; Feng L
    J Clin Oncol; 2005 Jul; 23(19):4450-7. PubMed ID: 15994154
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interim analyses in 2 x 2 crossover trials.
    Cook RJ
    Biometrics; 1995 Sep; 51(3):932-45. PubMed ID: 7548709
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Designing for cancer clinical trials: selection of prognostic factors.
    Brown BW
    Cancer Treat Rep; 1980; 64(2-3):499-502. PubMed ID: 7407790
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A general statistical principle for changing a design any time during the course of a trial.
    Müller HH; Schäfer H
    Stat Med; 2004 Aug; 23(16):2497-508. PubMed ID: 15287080
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of futility in clinical trials.
    Snapinn S; Chen MG; Jiang Q; Koutsoukos T
    Pharm Stat; 2006; 5(4):273-81. PubMed ID: 17128426
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incorporating intermediate binary responses into interim analyses of clinical trials: a comparison of four methods.
    Whitehead A; Sooriyarachchi MR; Whitehead J; Bolland K
    Stat Med; 2008 May; 27(10):1646-66. PubMed ID: 17886243
    [TBL] [Abstract][Full Text] [Related]  

  • 11. General statistical design considerations of randomized clinical trials.
    Peduzzi P
    Prog Clin Biol Res; 1988; 264():61-70. PubMed ID: 3289035
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biostatistics in clinical trials: Part 2. Determining sample sizes for clinical trials.
    Ellenberg SS
    Oncology (Williston Park); 1989 Aug; 3(8):39-46; discussion 48, 51. PubMed ID: 2519197
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomization as a basis for inference in noninferiority trials.
    Wiens BL
    Pharm Stat; 2006; 5(4):265-71. PubMed ID: 17128425
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stopping clinical trials because of treatment ineffectiveness: a comparison of a futility design with a method of stochastic curtailment.
    Whitehead J; Matsushita T
    Stat Med; 2003 Mar; 22(5):677-87. PubMed ID: 12587099
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Size of phase III cancer clinical trials.
    Simon R
    Cancer Treat Rep; 1985 Oct; 69(10):1087-93. PubMed ID: 4042088
    [No Abstract]   [Full Text] [Related]  

  • 16. Interim analyses in randomized clinical trials: ramifications and guidelines for practitioners.
    Geller NL; Pocock SJ
    Biometrics; 1987 Mar; 43(1):213-23. PubMed ID: 3567306
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The clinician as investigator: participating in clinical trials in the practice setting: Appendix 2: statistical concepts in study design and analysis.
    Lader EW; Cannon CP; Ohman EM; Newby LK; Sulmasy DP; Barst RJ; Fair JM; Flather M; Freedman JE; Frye RL; Hand MM; Jesse RL; Van de Werf F; Costa F;
    Circulation; 2004 Jun; 109(21):e305-7. PubMed ID: 15173053
    [No Abstract]   [Full Text] [Related]  

  • 18. Issues in the meta-analysis of cluster randomized trials.
    Donner A; Klar N
    Stat Med; 2002 Oct; 21(19):2971-80. PubMed ID: 12325113
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design and analytic concepts for periodontal clinical trials.
    Imrey PB; Chilton NW
    J Periodontol; 1992 Dec; 63(12 Suppl):1124-40. PubMed ID: 1479532
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sequential clinical trials in cancer research.
    George SL
    Cancer Treat Rep; 1980; 64(2-3):393-7. PubMed ID: 7407775
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.